Capricor Therapeutics (CAPR) stock
CAPR's Quality Score fell 1 point on Fri, Nov 13, to -7. Its daily price swings got bigger.
Follow CAPR's trial news. Pro members can get an alert when Capricor Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Key facts on CAPR
| Holding it back | 27.2% more shares than a year ago |
| Latest filing | 8-K, Nov 10 |
CAPR in the news
CAPR catalysts
After its last 4 reports it closed +18.0% on average, higher 2 of 4 times.
What's next for CAPR, and how long its cash lasts
Next step the company has named
Cash runway
About 6 quarters
Dilution on the horizon
- Shelf registration (S-3, filed Sep 10, 2025)
- At-the-market share sales program (S-3, filed Sep 10, 2025)
Insiders
CFO Anthony Bergmann sold 24,100 shares on Jun 25. 9 more insider trades this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Why CAPR scores -7
Poorfor quality, not price, 2 of 14 chart checks firingWhat the Quality Score means
- +2Chart checks 2 of 14 firing right now, one point each
- −2Long-term trend below a falling 200-day average, down over two years
- Profit subtracts
- Growth subtracts
- Dilution subtracts
- Volatility subtracts
- Cash flow subtracts
How CAPR ranks in Biotech
CAPR is #230 of 270 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 230 |
Cash and short-term investments: CAPR $198M, AGIO $630M, SVRA $130M, INO $48.4M.
When does CAPR report earnings, and what happens after?
Expected to report Thu Mar 11, after the close (in 115 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
What CAPR reported on Nov 10, 2026
The quarter
A loss of $0.73 a share, from $0.54.
“The increase was primarily driven by pre-commercial activities and manufacturing scale-up.”
Where the sales came from
CAPR's results filing gives no sales by line in a table we read.
The outlook
No outlook figures read from this release.
In the company's words
“The Company expects to provide additional guidance on its longer-term financial outlook following greater regulatory clarity, which will inform future strategic and capital allocation decisions.”
From its results filing (SEC filing · Nov 10)
The numbers
- $595M
- today
- $0
- down 100% on the year
- $105M
- last fiscal year
- -$72.7M
- last fiscal year
Its share count grew 15% a year over 5 years.
Close after the report, last 3
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 10, 2026 | +8.8% | +26.5% | not yet |
| Aug 13, 2026 | +82.0% | +58.0% | +62.4% |
| May 12, 2026 | -2.7% | -3.8% | -14.6% |
CAPR sales and profit by year
Sales grew in two of the last seven years, to $0 in 2025. It lost money in each of the eight years.
CAPR has 2 of 14 chart checks firing
CAPR RSI on Nov 13: 57.2, above its 50-day, below its 200-day
RSI 57.2, MACD above signal, above its 50-day, below its 200-day. Not scored.
The deep dive on CAPR
- What it does and how it makes money
- Where it standsSEC filing · Dec 5, 2025
- What changed in its filingsSEC filing · Mar 17, 2026, against the one of Mar 26, 2025
- Who holds and trades it
- Against its closest peers
CAPR insider trades
2 insiders sold $1.5M across 6 filings in the last 6 months. No open-market buys on record. The newest:
CAPR's officers and directors
Officers and directors with a Form 4 in the last 12 months.
Which ETFs hold CAPR?
In ETFs: CAPR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
About Capricor Therapeutics
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
What Capricor Therapeutics says it competes with
“We are engaged in fields that are characterized by extensive worldwide research and competition.”
Here is what Pro members see.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Pro members see every line of every stock's score.
- What would turn CAPR's score around: 9 things
- 7 more filings explained, a plain line each
- Real-time prices, no delay
Straight AnswersStraight Answers
What does CAPR's Quality Score say?
CAPR scores -7 today, which Breakaway calls Poor. It is #230 of 270 in Biotech by Quality Score, with 2 of 14 chart checks firing. Cash lasts about 6 quarters at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
What is CAPR's Quality Score?
CAPR scores -7 today, which Breakaway calls Poor (below zero). That is #230 of 270 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CAPR's -7.
Are insiders buying CAPR?
2 insiders sold $1.5M across 6 filings in the last 6 months. No open-market buys on record. The newest is Karen Krasney, EVP, General Counsel, who sold $732K on Jun 25. Every filing, with the scored weight, for Pro members.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.